CorMedix Says FDA Accepted REZZAYO Prophylaxis sNDA for Priority Review
CorMedix said the FDA accepted its supplemental application seeking approval of REZZAYO for prophylaxis. The application has a PDUFA target date in Q1 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.